个人中心 - 老虎社区

nutty

IP属地：未知

帖子 · 5帖子 · 5
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- nuttynutty
  ·2021-10-14
  To the moon
  Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>
  Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week. The bi
  Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>
  1,161 1
  5
  分享
  举报
- nuttynutty
  ·2021-08-20
  Aiya I take moderna vaccine
  Moderna COVID-19 vaccine being probed in U.S. for higher-than-expected risk of side effect<blockquote>Moderna COVID-19疫苗因副作用风险高于预期而在美国接受调查</blockquote>
  (Update: August 20, 2021 at 5:59 a.m. ET) The federal health officials are investigating whether the
  Moderna COVID-19 vaccine being probed in U.S. for higher-than-expected risk of side effect<blockquote>Moderna COVID-19疫苗因副作用风险高于预期而在美国接受调查</blockquote>
  947 评论
  1
  分享
  举报
- nuttynutty
  ·2021-06-23
  Nice
  非常抱歉，此主贴已删除
  932 1
  4
  分享
  举报
- nuttynutty
  ·2021-06-20
  Nice
  非常抱歉，此主贴已删除
  812 评论
  3
  分享
  举报
- nuttynutty
  ·2021-06-19
  Nice
  非常抱歉，此主贴已删除
  1,207 2
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3567403841737852","uuid":"3567403841737852","gmtCreate":1604390017326,"gmtModify":1622552915855,"name":"nutty","pinyin":"nutty","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f9cd364b7c52b6eaa92e0ba200e73000","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":7,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.01","exceedPercentage":"80.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.66%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":825230036,"gmtCreate":1634225847560,"gmtModify":1634225847560,"author":{"id":"3567403841737852","authorId":"3567403841737852","name":"nutty","avatar":"https://static.tigerbbs.com/f9cd364b7c52b6eaa92e0ba200e73000","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567403841737852","authorIdStr":"3567403841737852"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825230036","repostId":"1108820000","repostType":4,"repost":{"id":"1108820000","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634225594,"share":"https://www.laohu8.com/m/news/1108820000?lang=zh_CN&edition=full","pubTime":"2021-10-14 23:33","market":"us","language":"en","title":"Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108820000","media":"Tiger Newspress","summary":"Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.\n\nThe bi","content":"<p>Ocugen stock jumped more than 10% in morning trading.The share&nbsp;rose more than 40% this week.</p><p><blockquote>Ocugen股价早盘上涨超过10%。该股本周上涨超过40%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d6529ae3a1b252bbc25776ab15e3e3c\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.</p><p><blockquote>印度生物技术公司的股票今天上午向北移动，因为有消息称，新冠肺炎疫苗科瓦克辛获得了印度主题专家委员会对2至18岁儿童的紧急使用批准。这种疫苗是全世界首批获得如此广泛的紧急使用授权标签的疫苗之一。</blockquote></p><p> Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.</p><p><blockquote>Ocugen与印度的Bharat Biotech合作，在加拿大和美国将科瓦克辛商业化。两人现在正在等待世界卫生组织关于疫苗紧急使用申请的消息。这一关键的监管决定预计随时都会做出。</blockquote></p><p> Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.<b>Novavax</b>'s highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.</p><p><blockquote>Ocugen的目标是成为加拿大和美国等主要发达市场重要的二至三线COVID-19疫苗参与者。这种策略的问题在于，在这些高价值地区，新型冠状病毒疫苗已经过剩，而且还会有更多疫苗。<b>Novavax</b>例如，备受期待的COVID-19疫苗NVX-CoV2373将于2022年初在美国上市。因此，目前还不完全清楚像Ocugen这样的后来者会留下多少商业机会。</blockquote></p><p> Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.</p><p><blockquote>受此消息影响，Ocugen的股票值得买入吗？可以肯定的是，这是一个极其积极的监管发展。但这不太可能对该疫苗在加拿大或美国的监管命运产生任何影响。</blockquote></p><p> That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.</p><p><blockquote>也就是说，从长远来看，该生物技术公司的股价仍应表现良好。如果该疫苗能够在该公司拥有商业许可证的日益拥挤的市场中开辟一个有利可图的利基市场，那么Ocugen最终可能会获得健康且或许相当长期的收入流。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-14 23:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ocugen stock jumped more than 10% in morning trading.The share&nbsp;rose more than 40% this week.</p><p><blockquote>Ocugen股价早盘上涨超过10%。该股本周上涨超过40%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d6529ae3a1b252bbc25776ab15e3e3c\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.</p><p><blockquote>印度生物技术公司的股票今天上午向北移动，因为有消息称，新冠肺炎疫苗科瓦克辛获得了印度主题专家委员会对2至18岁儿童的紧急使用批准。这种疫苗是全世界首批获得如此广泛的紧急使用授权标签的疫苗之一。</blockquote></p><p> Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.</p><p><blockquote>Ocugen与印度的Bharat Biotech合作，在加拿大和美国将科瓦克辛商业化。两人现在正在等待世界卫生组织关于疫苗紧急使用申请的消息。这一关键的监管决定预计随时都会做出。</blockquote></p><p> Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.<b>Novavax</b>'s highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.</p><p><blockquote>Ocugen的目标是成为加拿大和美国等主要发达市场重要的二至三线COVID-19疫苗参与者。这种策略的问题在于，在这些高价值地区，新型冠状病毒疫苗已经过剩，而且还会有更多疫苗。<b>Novavax</b>例如，备受期待的COVID-19疫苗NVX-CoV2373将于2022年初在美国上市。因此，目前还不完全清楚像Ocugen这样的后来者会留下多少商业机会。</blockquote></p><p> Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.</p><p><blockquote>受此消息影响，Ocugen的股票值得买入吗？可以肯定的是，这是一个极其积极的监管发展。但这不太可能对该疫苗在加拿大或美国的监管命运产生任何影响。</blockquote></p><p> That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.</p><p><blockquote>也就是说，从长远来看，该生物技术公司的股价仍应表现良好。如果该疫苗能够在该公司拥有商业许可证的日益拥挤的市场中开辟一个有利可图的利基市场，那么Ocugen最终可能会获得健康且或许相当长期的收入流。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108820000","content_text":"Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.\n\nThe biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.\nOcugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.\nOcugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.Novavax's highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.\nIs Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.\nThat said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":836332706,"gmtCreate":1629453872005,"gmtModify":1631889980285,"author":{"id":"3567403841737852","authorId":"3567403841737852","name":"nutty","avatar":"https://static.tigerbbs.com/f9cd364b7c52b6eaa92e0ba200e73000","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567403841737852","authorIdStr":"3567403841737852"},"themes":[],"htmlText":"Aiya I take moderna vaccine","listText":"Aiya I take moderna vaccine","text":"Aiya I take moderna vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/836332706","repostId":"1189046360","repostType":4,"repost":{"id":"1189046360","kind":"news","pubTimestamp":1629448332,"share":"https://www.laohu8.com/m/news/1189046360?lang=zh_CN&edition=full","pubTime":"2021-08-20 16:32","market":"us","language":"en","title":"Moderna COVID-19 vaccine being probed in U.S. for higher-than-expected risk of side effect<blockquote>Moderna COVID-19疫苗因副作用风险高于预期而在美国接受调查</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1189046360","media":"Seeking Alpha","summary":"(Update: August 20, 2021 at 5:59 a.m. ET)\nThe federal health officials are investigating whether the","content":"<p><i><b>(Update: August 20, 2021 at 5:59 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年8月20日上午5:59）</b></i></blockquote></p><p> The federal health officials are investigating whether the COVID-19 vaccine developed by <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> (NASDAQ:&nbsp;MRNA)is linked to even a higher risk of a rare side effect called myocarditis in younger adults than initially expected,&nbsp;<i>The WashingtonPost</i>&nbsp;reported citing people familiar with the matter.</p><p><blockquote>联邦卫生官员正在调查由<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>（纳斯达克：MRNA）与年轻人患心肌炎这种罕见副作用的风险甚至比最初预期的更高有关，<i>华盛顿邮报</i>报道援引知情人士的话称。</blockquote></p><p> The people have stressed that the side effect affecting the heart “probably” continues to be uncommon. The probe has involved the officials from the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).</p><p><blockquote>人们强调，影响心脏的副作用“可能”仍然不常见。该调查涉及食品药品监督管理局（FDA）和疾病控制与预防中心（CDC）的官员。</blockquote></p><p> The investigation is reportedly focused on emerging data from Canada indicating that the vaccine carries a higher risk in the younger population than that from the rival COVID-19 shot from <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>&nbsp;(NYSE:&nbsp;PFE)&nbsp;and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (NASDAQ:&nbsp;BNTX), in males below the age of 30 or so in particular.</p><p><blockquote>据报道，这项调查的重点是来自加拿大的新数据，这些数据表明该疫苗在年轻人群中的风险比来自加拿大的竞争对手COVID-19疫苗更高<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>（纽约证券交易所代码：PFE）和<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>（纳斯达克：BNTX），尤其是在30岁以下的男性中。</blockquote></p><p> The authorities are trying to establish whether the U.S. data also suggest a higher risk from Moderna’s (MRNA) vaccine in the population.</p><p><blockquote>当局正试图确定美国的数据是否也表明Moderna(MRNA)疫苗在人群中的风险更高。</blockquote></p><p> <li>In June, the FDA moved to update the fact sheets of Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) vaccines to reflect the likelihood of rare cases of heart&nbsp;inflammation following their administration.</p><p><blockquote><li>6月，FDA更新了辉瑞(PFE)/BioNTech(BNTX)和Moderna(MRNA)疫苗的情况说明书，以反映接种后出现罕见心脏炎症病例的可能性。</li></blockquote></p><p>Moderna&nbsp;sink&nbsp;over&nbsp;2%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote>Moderna在盘前交易中下跌超过2%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e4e9a64ce0c6eb83275b67dbd3b00b4c\" tg-width=\"917\" tg-height=\"391\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></li></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine being probed in U.S. for higher-than-expected risk of side effect<blockquote>Moderna COVID-19疫苗因副作用风险高于预期而在美国接受调查</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine being probed in U.S. for higher-than-expected risk of side effect<blockquote>Moderna COVID-19疫苗因副作用风险高于预期而在美国接受调查</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-20 16:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i><b>(Update: August 20, 2021 at 5:59 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年8月20日上午5:59）</b></i></blockquote></p><p> The federal health officials are investigating whether the COVID-19 vaccine developed by <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> (NASDAQ:&nbsp;MRNA)is linked to even a higher risk of a rare side effect called myocarditis in younger adults than initially expected,&nbsp;<i>The WashingtonPost</i>&nbsp;reported citing people familiar with the matter.</p><p><blockquote>联邦卫生官员正在调查由<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>（纳斯达克：MRNA）与年轻人患心肌炎这种罕见副作用的风险甚至比最初预期的更高有关，<i>华盛顿邮报</i>报道援引知情人士的话称。</blockquote></p><p> The people have stressed that the side effect affecting the heart “probably” continues to be uncommon. The probe has involved the officials from the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).</p><p><blockquote>人们强调，影响心脏的副作用“可能”仍然不常见。该调查涉及食品药品监督管理局（FDA）和疾病控制与预防中心（CDC）的官员。</blockquote></p><p> The investigation is reportedly focused on emerging data from Canada indicating that the vaccine carries a higher risk in the younger population than that from the rival COVID-19 shot from <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>&nbsp;(NYSE:&nbsp;PFE)&nbsp;and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (NASDAQ:&nbsp;BNTX), in males below the age of 30 or so in particular.</p><p><blockquote>据报道，这项调查的重点是来自加拿大的新数据，这些数据表明该疫苗在年轻人群中的风险比来自加拿大的竞争对手COVID-19疫苗更高<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>（纽约证券交易所代码：PFE）和<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>（纳斯达克：BNTX），尤其是在30岁以下的男性中。</blockquote></p><p> The authorities are trying to establish whether the U.S. data also suggest a higher risk from Moderna’s (MRNA) vaccine in the population.</p><p><blockquote>当局正试图确定美国的数据是否也表明Moderna(MRNA)疫苗在人群中的风险更高。</blockquote></p><p> <li>In June, the FDA moved to update the fact sheets of Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) vaccines to reflect the likelihood of rare cases of heart&nbsp;inflammation following their administration.</p><p><blockquote><li>6月，FDA更新了辉瑞(PFE)/BioNTech(BNTX)和Moderna(MRNA)疫苗的情况说明书，以反映接种后出现罕见心脏炎症病例的可能性。</li></blockquote></p><p>Moderna&nbsp;sink&nbsp;over&nbsp;2%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote>Moderna在盘前交易中下跌超过2%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e4e9a64ce0c6eb83275b67dbd3b00b4c\" tg-width=\"917\" tg-height=\"391\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></li></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3732568-moderna-covid-19-vaccine-being-probed-in-us-for-higher-than-expected-risk-of-side-effect\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3732568-moderna-covid-19-vaccine-being-probed-in-us-for-higher-than-expected-risk-of-side-effect","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189046360","content_text":"(Update: August 20, 2021 at 5:59 a.m. ET)\nThe federal health officials are investigating whether the COVID-19 vaccine developed by Moderna, Inc. (NASDAQ: MRNA)is linked to even a higher risk of a rare side effect called myocarditis in younger adults than initially expected, The WashingtonPost reported citing people familiar with the matter.\nThe people have stressed that the side effect affecting the heart “probably” continues to be uncommon. The probe has involved the officials from the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).\nThe investigation is reportedly focused on emerging data from Canada indicating that the vaccine carries a higher risk in the younger population than that from the rival COVID-19 shot from Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), in males below the age of 30 or so in particular.\nThe authorities are trying to establish whether the U.S. data also suggest a higher risk from Moderna’s (MRNA) vaccine in the population.\nIn June, the FDA moved to update the fact sheets of Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) vaccines to reflect the likelihood of rare cases of heart inflammation following their administration.Moderna sink over 2% in premarket trading.","news_type":1,"symbols_score_info":{"PFE":0.9,"MRNA":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123972534,"gmtCreate":1624407808128,"gmtModify":1631889980288,"author":{"id":"3567403841737852","authorId":"3567403841737852","name":"nutty","avatar":"https://static.tigerbbs.com/f9cd364b7c52b6eaa92e0ba200e73000","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567403841737852","authorIdStr":"3567403841737852"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/123972534","repostId":"2145664330","repostType":4,"isVote":1,"tweetType":1,"viewCount":932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164084263,"gmtCreate":1624161696252,"gmtModify":1631889980289,"author":{"id":"3567403841737852","authorId":"3567403841737852","name":"nutty","avatar":"https://static.tigerbbs.com/f9cd364b7c52b6eaa92e0ba200e73000","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567403841737852","authorIdStr":"3567403841737852"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164084263","repostId":"2144218770","repostType":4,"isVote":1,"tweetType":1,"viewCount":812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165193073,"gmtCreate":1624102892892,"gmtModify":1631889980293,"author":{"id":"3567403841737852","authorId":"3567403841737852","name":"nutty","avatar":"https://static.tigerbbs.com/f9cd364b7c52b6eaa92e0ba200e73000","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567403841737852","authorIdStr":"3567403841737852"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/165193073","repostId":"1113942445","repostType":4,"isVote":1,"tweetType":1,"viewCount":1207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}